5629-98-1

Basic information

• Product Name: N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide
• Synonyms: N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide
• CAS NO: 5629-98-1
• Molecular Formula: C₇H₄Br₂O
• Molecular Weight: 263.91
• Product Categories: Adehydes, Acetals & Ketones;Bromine Compounds
• Mol File: 5629-98-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 80 °C
• Boiling Point: 533.2°Cat760mmHg
• Flash Point: 276.3°C
• Appearance: /
• Density: 1.105g/cm³
• Vapor Pressure: 0.00198mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide(5629-98-1)
• EPA Substance Registry System: N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide(5629-98-1)

Safety Data

• Hazardous Substances Data: 5629-98-1(Hazardous Substances Data)

Usage

General Description

N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide is a chemical compound with the molecular formula C19H27N2O3. It is a synthetic organic compound often used in pharmaceutical research and drug development. The compound is a potential analgesic and anti-inflammatory agent due to its structural resemblance to certain classes of nonsteroidal anti-inflammatory drugs (NSAIDs). N-(4-dimethylaminophenyl)-2-(5-methyl-2-propan-2-yl-phenoxy)acetamide may also have potential applications in the treatment of various pain and inflammation-related conditions. However, as with all chemical compounds, it should be handled and used with caution, following proper safety protocols.

InChI:InChI=1/C7H4Br2O/c8-6-2-1-5(4-10)7(9)3-6/h1-4H

Upstream product

• 1184179-43-8 C₇H₄Br₄ 
• 64382-92-9 2,4-dibromo-1-(bromomethyl)benzene 
• 7745-93-9 2-bromo-4-nitrotoluene 
• 7745-91-7 3-bromo-4-methylaniline 
• 615-57-6 2,4-dibromo-aniline 
• 78222-69-2 2,4-dibromobenzonitrile 
• 31543-75-6 2,4-dibromotoluene 
• 3473-11-8 formaldehyde oxime hydrochloride 

Downstream Products

• 69258-54-4 N⁴-[2-(2,4-dibromo-styryl)-quinazolin-4-yl]-N¹,N¹-diethyl-pentane-1,4-diamine 
• 69258-56-6 N⁴-[7-chloro-2-(2,4-dibromo-styryl)-quinazolin-4-yl]-N¹,N¹-diethyl-pentane-1,4-diamine 
• 666747-06-4 (2,4-dibromophenyl)methanol 
• 331714-59-1 2,4-dicyanobenzaldehyde 
• 331714-61-5 2-(2,4-dicyanophenyl)-1,3-dioxolane 
• 1285505-86-3 N-[(E)-3-(2,4-dibromo-phenyl)-2-methyl-acryloyl]-guanidine 
• 1285505-91-0 C₁₀H₈Br₂O₂ 
• 24162-63-8 2,4-dibromostyrene 

Relevant articles and documents

Copper-catalyzed recycling of halogen activating groups via 1,3-halogen migration

A Cu(I)-catalyzed 1,3-halogen migration reaction effectively recycles an activating group by transferring bromine or iodine from a sp2 to a benzylic carbon with concomitant borylation of the Ar-X bond. The resulting benzyl halide can be reacted in the same vessel under a variety of conditions to form an additional carbon-heteroatom bond. Cross-over experiments using an isotopically enriched bromide source support intramolecular transfer of Br. The reaction is postulated to proceed via a Markovnikov hydrocupration of the o-halostyrene, oxidative addition of the resulting Cu(I) complex into the Ar-X bond, reductive elimination of the new sp3 C-X bond, and final borylation of an Ar-Cu(I) species to turn over the catalytic cycle.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.